CA2692784A1 - Compositions et methodes pour le diagnostic et l'evaluation de myopathies inflammatoires - Google Patents

Compositions et methodes pour le diagnostic et l'evaluation de myopathies inflammatoires Download PDF

Info

Publication number
CA2692784A1
CA2692784A1 CA 2692784 CA2692784A CA2692784A1 CA 2692784 A1 CA2692784 A1 CA 2692784A1 CA 2692784 CA2692784 CA 2692784 CA 2692784 A CA2692784 A CA 2692784A CA 2692784 A1 CA2692784 A1 CA 2692784A1
Authority
CA
Canada
Prior art keywords
interferon
genes
induced
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2692784
Other languages
English (en)
Other versions
CA2692784C (fr
Inventor
Steven Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692784A1 publication Critical patent/CA2692784A1/fr
Application granted granted Critical
Publication of CA2692784C publication Critical patent/CA2692784C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

L'invention concerne des méthodes de dosage pour des myopathies inflammatoires, ainsi que des plaques à microréseau pour l'exécution de ces dosages.
CA2692784A 2007-07-12 2008-07-07 Compositions et methodes pour le diagnostic et l'evaluation de myopathies inflammatoires Active CA2692784C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92977507P 2007-07-12 2007-07-12
US60/929,775 2007-07-12
PCT/US2008/008333 WO2009011770A2 (fr) 2007-07-12 2008-07-07 Compositions et méthodes pour le diagnostic et l'évaluation de myopathies inflammatoires

Publications (2)

Publication Number Publication Date
CA2692784A1 true CA2692784A1 (fr) 2009-01-22
CA2692784C CA2692784C (fr) 2018-10-02

Family

ID=40260241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2692784A Active CA2692784C (fr) 2007-07-12 2008-07-07 Compositions et methodes pour le diagnostic et l'evaluation de myopathies inflammatoires

Country Status (7)

Country Link
US (2) US20100190659A1 (fr)
EP (3) EP2666873B1 (fr)
JP (2) JP5726524B2 (fr)
AU (1) AU2008276594B2 (fr)
CA (1) CA2692784C (fr)
ES (2) ES2542836T3 (fr)
WO (1) WO2009011770A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024236A1 (fr) * 2010-08-14 2012-02-23 Biogen Idec Ma Inc. Blocage des ltβr : procédés pour optimiser la sensibilité thérapeutique de patients
AU2022260531B2 (en) 2021-04-23 2024-03-07 Astrazeneca Ab Anti-ifnar1 dosing regime for subcutaneous injection

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5622826A (en) 1994-12-22 1997-04-22 Houston Advanced Research Center Method for immobilization of molecules on platinum solid support surfaces
JP4663824B2 (ja) 1996-12-31 2011-04-06 ハイ スループット ジェノミクス インコーポレイテッド 多重化分子分析装置および方法
US6235473B1 (en) 1998-07-02 2001-05-22 Orchid Biosciences, Inc. Gene pen devices for array printing
WO2001062377A2 (fr) 2000-02-22 2001-08-30 Genospectra, Inc. Techniques et dispositif de fabrication de jeux ordonnes de microechantillons
US7157227B2 (en) 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
US6902702B1 (en) 2000-08-16 2005-06-07 University Health Network Devices and methods for producing microarrays of biological samples
EP1442142A4 (fr) 2001-10-19 2006-11-15 Proligo Llc Sondes d'acide nucleique et procedes de detection et/ou de quantification d'analytes d'acide nucleique
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
CN101473045B (zh) * 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
WO2008070137A2 (fr) * 2006-12-06 2008-06-12 Medimmune, Llc Marqueurs pharmacodynamiques alpha-induit d'interféron
US20100261172A1 (en) * 2007-05-03 2010-10-14 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US20100266610A1 (en) * 2007-05-03 2010-10-21 Medimmune, Llc Auto-antibody markers of autoimmune disease
US20080279851A1 (en) * 2007-05-07 2008-11-13 Medlmmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2714410A1 (fr) * 2008-02-08 2009-08-13 Medimmune, Llc Marqueurs de troubles et leur utilisation
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers

Also Published As

Publication number Publication date
JP2010533296A (ja) 2010-10-21
EP2167679A2 (fr) 2010-03-31
JP2015128449A (ja) 2015-07-16
EP2666873A1 (fr) 2013-11-27
CA2692784C (fr) 2018-10-02
AU2008276594A1 (en) 2009-01-22
US20100190659A1 (en) 2010-07-29
AU2008276594B2 (en) 2014-03-20
WO2009011770A8 (fr) 2010-03-11
EP2666874B1 (fr) 2015-05-27
ES2542836T3 (es) 2015-08-12
WO2009011770A3 (fr) 2009-03-12
JP5726524B2 (ja) 2015-06-03
EP2666874A1 (fr) 2013-11-27
WO2009011770A2 (fr) 2009-01-22
US20150337380A1 (en) 2015-11-26
EP2167679A4 (fr) 2011-01-12
EP2666873B1 (fr) 2016-03-09
ES2567094T3 (es) 2016-04-19

Similar Documents

Publication Publication Date Title
AU2020201564B2 (en) Diagnostic for sepsis
Singh et al. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy
US11286529B2 (en) Diagnostic methods for infectious disease using endogenous gene expression
EP3268499A1 (fr) Méthodes de diagnostic de la sepsie
CN102459651A (zh) 测定对免疫调节组合物治疗的应答的方法
WO2015155517A1 (fr) Prédicteurs moléculaires de la septicémie
EP2145964A1 (fr) Procédé de détection précoce du cancer des poumons et pronostic
EP2527473A2 (fr) Signature de lymphocyte B associée à une tolérance chez les receveurs d'une greffe
AU2008276594B2 (en) Compositions and methods for diagnosing and assessing inflammatory myopathies
JP2010533296A5 (fr)
CN114729402A (zh) 用于确定个体对刺激物作出反应的能力的方法
US20110257888A1 (en) Method of determining chronic fatigue syndrome
KR101568731B1 (ko) 만성폐쇄성폐질환 진단용 마커 조성물
KR101180879B1 (ko) 천식 진단용 유전자 마커 및 이를 이용한 천식 진단에 필요한 정보를 제공하는 방법
KR20130100640A (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
KR20200002237A (ko) 비만 진단을 위한 마이크로RNA let-7a 또는 let-7f 바이오마커 및 이의 용도
US20160265058A1 (en) Diagnostic methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130703